![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/Hartung_Pic.neu_-e1599660273703.jpg)
EAN 2019
![](https://conferences.medicom-publishers.com/wp-content/uploads/2021/02/EAN_MCR_2019-Cover_C1-1-225x300.png)
Read the full Report (pdf)
European Academy of Neurology
29 June – 2 July 2019 Oslo, Norway
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/Hartung_Pic.neu_-e1599660273703.jpg)
CONTENTS
Online First
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/09/EAN_MCR_2019_D1-Digitaal-5-1024x674.png)
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Panel of inflammation-associated microRNAs as epilepsy biomarker
Clinical and cost effectiveness of levetiracetam vs valproate
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Atogepant efficacious, safe, and well-tolerated for migraine prevention
Short- and long-term efficacy of erenumab in hard-to-treat patients
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/09/EAN_MCR_2019_D1-Digitaal-10a-1024x309.png)
Fremanezumab results of the FOCUS study
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/09/EAN_MCR_2019_D1-Digitaal-10b-1024x384.png)
Galcanezumab reduces healthcare resource utilisation
Lasmiditan in migraine patients with CV risk factors
Factors influencing choice of prophylactic migraine therapy
Multiple Sclerosis
Treating MS from disease onset
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/09/EAN_MCR_2019_D1-Digitaal-12-1024x501.png)
Long-term effects of established treatments
Randomised and observational studies comparing treatments
![](https://conferences.medicom-publishers.com/wp-content/uploads/2019/09/EAN_MCR_2019_D1-Digitaal-15-1024x466.png)